DURHAM, N.C. / Nov 19, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral presentation at the Hep-DART 2025 meeting , to take place December 7–11, 2025, at the Hilton Hawaiian Village in Honolulu, Hawaii. The... Read More

DURHAM, N.C. / Nov 10, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purchase up to... Read More

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking AASLD session at 5:45pm EST on Monday, November 10, 2025 PBGENE-HBV was well-tolerated across pre-planned repeat administrations at doses of 0.2mg/kg, 0.4 mg/kg, and 0.8mg/kg with no dose-limiting toxicities Data to date from... Read More

Late-breaking oral presentation at the Liver Meeting ® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B Commenced dosing in Cohort 3 of the ELIMINATE-B trial with additional data readouts planned in early 2026 Investigational new drug (IND) filing for PBGENE-DMD anticipated by end of 2025; Phase 1 initiation in Duchenne Muscular Dystrophy (DMD) patients... Read More

DURHAM, N.C. / Oct 31, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025. About Precision BioSciences, Inc. Precision... Read More

DURHAM, N.C. / Oct 14, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at the Liver Meeting ® 2025. The oral presentation will feature new PBGENE-HBV data from the... Read More

Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and replacement of large stretches of genomic DNA DURHAM, N.C. / Oct 09, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to... Read More

Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites Phase 1 ELIMINATE-B trial for PBGENE-HBV is progressing and on track to report additional data from higher dose cohorts in 2025 DURHAM, N.C. / Oct 07, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel... Read More

Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy On track to file an IND and/or CTA by the end of 2025; clinical data anticipated in 2026 DURHAM, N.C. / Sep 30, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in... Read More

DURHAM, N.C. / Sep 12, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the... Read More

Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042 Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025 DURHAM, N.C. / Sep 08, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ®... Read More

Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69% reduction in Hepatitis B surface antigen (HBsAg) and durable HBsAg reduction in one patient 7 months after initial dose administration... Read More

Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of complete cure Cohort 1, the lowest dose cohort (0.2 mg/kg) of ELIMINATE-B, established a safe and well-tolerated profile across multiple dose administrations for all patients PBGENE-HBV demonstrated substantial antiviral activity... Read More

DURHAM, N.C. / Aug 04, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc.... Read More

DURHAM, N.C. / Jul 23, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).... Read More

New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, potentially driven by editing of muscle satellite cells PBGENE-DMD is a first-in-class in vivo gene editing approach for up to 60% of Duchenne Muscular Dystrophy patients, specifically those impacted by dystrophin mutations in the ‘hot spot’ region between exons 45-55... Read More

DURHAM, N.C. / Jun 25, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy... Read More

Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision’s in vivo gene editing approach Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoing clinical updates anticipated throughout 2025 Received regulatory clearance of IND from the U.S. FDA to expand ELIMINATE-B trial and CTA... Read More

PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot’ region between exons 45-55 Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial... Read More

DURHAM, N.C. / May 08, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision... Read More

DURHAM, N.C. / May 07, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a... Read More

DURHAM, N.C. / May 01, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that five abstracts detailing Precision’s wholly owned or partnered programs have been accepted for presentation at the... Read More

DURHAM, N.C. / Apr 29, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on April 22, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the... Read More

DURHAM, N.C. / Apr 15, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PBGENE-HBV, the Company’s lead wholly owned in vivo gene editing... Read More

DURHAM, N.C. / Apr 01, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24 th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025.... Read More

Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis... Read More

DURHAM, N.C. / Mar 21, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March... Read More

PBGENE-HBV, the first and only clinical stage gene editing therapy for chronic hepatitis B Repeat dosing of PBGENE-HBV supported by definitive preclinical safety and toxicology studies ELIMINATE-B global Phase 1 study for chronic hepatitis B actively enrolling patients and will evaluate up to three dose administrations of PBGENE-HBV at each dose level Precision remains on track to continue reporting clinical data throughout... Read More

Potential first-in-class gene editing approach designed for dystrophin gene correction leading the body to produce a functional dystrophin protein applicable for majority of DMD patients (up to ~60%) PBGENE-DMD restored dystrophin protein expression and significantly improved muscle function over time while demonstrating long-term durability in an in vivo DMD disease model PBGENE-DMD dystrophin gene correction observed in... Read More

PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared to enter clinical trials for the treatment of chronic hepatitis B in the United States (U.S.) IND clearance represents a significant regulatory milestone for PBGENE-HBV Company to expand its Phase 1 ELIMINATE-B study to the U.S., joining world-class clinical sites in Moldova, Hong Kong, and New Zealand where strong clinical execution is... Read More

DURHAM, N.C. / Feb 24, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that the company will present preclinical data from the PBGENE-DMD program for the treatment of Duchenne muscular... Read More

ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing technology studied for Hepatitis B, was safe and well tolerated PBGENE-HBV demonstrated substantial antiviral activity measured by reduction of Hepatitis B surface antigen (HBsAg) after one administration at the lowest dose level... Read More

Cindy Atwell, promoted to Chief Development and Business Officer Cassie Gorsuch, PhD, promoted to Chief Scientific Officer DURHAM, N.C. / Jan 29, 2025 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today... Read More

Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) ECUR-506 was generally well tolerated with no significant clinical safety concerns Insertion of a functional OTC gene through ARCUS in vivo gene editing may provide lasting clinical benefit for children with OTC deficiency who are in dire need of effective treatments DURHAM, N.C. /... Read More

First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level (1.3 x 10 13 GC/kg) of ECUR-506 from three months post exposure to the end of study (six months post exposure) as demonstrated by the removal of standard of care ammonia scavenging medicines, followed by absence of hyperammonemic crises and normalization of protein intake The... Read More

Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024 ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected to report clinical data as it matures throughout 2025 U.S. investigational new drug (IND) anticipated in 2025 DURHAM, N.C. / Dec 18, 2024 /... Read More

DURHAM, N.C. / Nov 21, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. JonesTrading Virtual Genetic Medicine Day Date: Monday, November 25, 2024 Time: 11:00 AM ET... Read More

PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by durable reduction of key viral biomarkers Global study recruiting patients following clearance of first clinical trial application (CTA),... Read More

Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval Opened PBGENE-HBV phase 1 clinical program in Moldova; patient screening underway with clinical data expected in 2025 Strengthened infectious disease capabilities with key clinical talent added to senior leadership team... Read More

DURHAM, N.C. / Oct 29, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision... Read More

DURHAM, N.C. / Oct 28, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B Investor Event on Friday, November 15, 2024, from 7:00 a.m. – 8:30 a.m. PST prior to the American Association for the Study of Liver... Read More

Stimulating gene editing by homology-directed repair (HDR) has the potential advantage of being able to achieve any type of edit, including gene insertion ARCUS approach potentially offers broader therapeutic than current gene editing modalities for diseases that require a gain in function DURHAM, N.C. / Oct 24, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing... Read More

Clinical Trial Application accepted in Moldova with additional regulatory applications pending approval PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials Company to host investor event highlighting clinical candidate safety data and plans for the Phase 1 trial prior to American Association for the Study of Liver Diseases Annual Meeting DURHAM, N.C. / Oct... Read More

DURHAM, N.C. / Oct 21, 2024 / Business Wire / Precision BioSciences, Inc . (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences. Longwood Boston CEO Conference Date: Monday, October 28, 2024 Time: 11:10 AM ET Title:... Read More

DURHAM, N.C. / Oct 16, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for diseases where a defective gene is remedied by expression of a new DNA sequence, today announced a poster presentation at the upcoming... Read More

DURHAM, N.C. / Oct 03, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits including viral gene elimination, today announced that the Company will present during a fireside chat at the H.C. Wainwright 5 th Annual Viral Hepatitis Virtual Conference taking place... Read More

PBGENE-HBV is the only drug modality designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV Clinical trial applications submitted for the first gene editing approach for chronic hepatitis B Final clinical candidate safety data and plans for the Phase 1 trial to be shared in November prior to the American Association for the Study of Liver Diseases meeting DURHAM, N.C. / Sep 30,... Read More

DURHAM, N.C. / Sep 20, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that, on September 18, 2024, the Compensation Committee of Precision’s Board of Directors approved the... Read More

Murray Abramson, MD, MPH appointed as Senior Vice President, Head of Clinical Development John Fry appointed as Strategic Clinical Advisor, Hepatitis Alan List, MD, Chief Medical Officer to Retire and Assume Role as Clinical Consultant as part of Precision’s Scientific Advisory Board DURHAM, N.C. / Sep 12, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel... Read More

DURHAM, N.C. / Sep 04, 2024 / Business Wire / Precision BioSciences, Inc . (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that the Company will participate in a panel discussion and fireside chat at the H.C. Wainwright 26 th... Read More

Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares The addition of this cash further reinforces Precision’s expected cash runway into the second half of 2026 DURHAM, N.C. / Sep 03, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated... Read More

Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. / Aug 09, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene excision, today announced that its partner TG... Read More

Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs;... Read More

DURHAM, N.C. / Jul 31, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will participate in the following upcoming investor conferences in August. In addition, Precision’s... Read More

DURHAM, N.C. / Jul 29, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene... Read More

DURHAM, N.C. / Jul 08, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that the company will present at the upcoming JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California. Presentation Details: Date: Monday, July 15, 2024 Time:... Read More

DURHAM, N.C. / Jul 01, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russell Microcap® Index. Precision’s inclusion in the index follows the conclusion of the 2024... Read More

DURHAM, N.C. / Jun 27, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference being held... Read More

DURHAM, N.C. / Jun 20, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board... Read More

PBGENE-HBV specifically cuts HBV DNA without impacting the human genome PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed Preclinical safety data supports advancement of PBGENE-HBV to clinical trials as a potentially curative, finite treatment for chronic hepatitis B with IND and/or CTA on-track for submission in 2024 DURHAM, N.C. / Jun 05, 2024 / Business Wire / Precision... Read More

DURHAM, N.C. / May 30, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that members of management will participate in the following upcoming investor conferences in June: Jefferies Global... Read More

DURHAM, N.C. / May 17, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement... Read More

Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 First ARCUS in vivo gene editing program now open for enrollment in the United Kingdom through partnered OTC deficiency program; United States and Australia expected to follow Exercised option to return three advanced preclinical programs for development internally... Read More

DURHAM, N.C. / May 08, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will... Read More

DURHAM, N.C. / May 07, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13,... Read More

DURHAM, N.C. / May 07, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that its partner iECURE has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for... Read More

Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024 DURHAM, N.C. / May 01, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,... Read More

- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners - Precision’s most important near-term clinical priorities in Hepatitis B (HBV) and Primary Mitochondrial Myopathy (PMM) and the expected cash... Read More

Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 Completed licensing agreements to monetize divested CAR T assets with Imugene, TG Therapeutics and Caribou Biosciences including nearly $50 million in upfront and potential near-term payments Completed $40 million in public offering extending our anticipated cash runway into the second half of... Read More

DURHAM, N.C. / Mar 20, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on... Read More

Data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS’ ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing PBGENE-PMM shifted heteroplasmy by eliminating mutant m.3243 mitochondrial DNA (mtDNA) while repopulating wild type mtDNA, leading to improved mitochondrial function in cells Precision expects to submit a CTA and/or IND for... Read More

Insertion of a functional OTC gene through ARCUS in vivo gene editing may provide lasting clinical benefit for children with OTC deficiency who are in dire need for effective treatments CTA approval for ECUR-506 in the United Kingdom provides further regulatory support for Precision BioSciences’ ARCUS in vivo gene editing platform DURHAM, N.C. / Mar 06, 2024 / Business Wire / Precision BioSciences, Inc . (Nasdaq: DTIL), an... Read More

DURHAM, N.C. / Mar 01, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it has agreed to sell to the public by way of an underwritten offering 2,500,000 shares of its... Read More

DURHAM, N.C. / Feb 29, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced the commencement of a proposed underwritten public offering of its common stock and accompanying... Read More

DURHAM, N.C. / Feb 20, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a... Read More

Regulatory feedback and alignment from both U.S. and ex-U.S. regulators supports clinical development path for PBGENE-HBV IND/CTA enabling studies with final clinical candidate underway for PBGENE-HBV program; expect to file IND and/or CTA in 2024 Expected to be the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate cccDNA and inactivate integrated HBV DNA... Read More

Dedicated Senior-Level Function will Enhance and Expand Existing Strategic IR Program DURHAM, N.C. / Feb 13, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that Naresh Tanna, Chief of... Read More

DURHAM, N.C. / Feb 12, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today received an upfront cash payment and equity investment from TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to... Read More

DURHAM, N.C. / Feb 09, 2024 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock. The reverse... Read More

Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments Upfront Cash and Near-Term Payments Expected to Extend Precision’s Cash Runway into the First Half of 2026 and Fund Precision’s Wholly-Owned In Vivo Gene Editing Programs Through PBGENE-HBV and PBGENE-PMM Phase I Clinical Data DURHAM, N.C. / Jan 09, 2024 / Business Wire /... Read More

OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study DURHAM, N.C. / Dec 13, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and... Read More

Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity mitoARCUS efficiently shifted m.3243A>G heteroplasmy without off-target activity, leading to an overall improvement in mitochondrial function DURHAM, N.C. / Dec 04, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company... Read More

DURHAM, N.C. / Nov 30, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5,... Read More

DURHAM, N.C. / Nov 28, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an... Read More

PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at maximal on-target editing dose PBGENE-HBV final clinical candidate ready with CTA and/or IND filing targeted in 2024 Company to host webcast at 4:30 pm ET on Monday, November 13, 2023 DURHAM, N.C. / Nov 13, 2023 / Business Wire /... Read More

DURHAM, N.C. / Nov 10, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023. Details... Read More

Company to Host Webcast and Conference Call on Monday, November 13, 2023 at 4:30 PM ET DURHAM, N.C. / Nov 09, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that an abstract featuring... Read More

Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023 Hosted R&D Day highlighting exclusive focus on in vivo gene editing pipeline Expanded portfolio with PBGENE-PMM as a potentially curative treatment for m.3243 associated primary mitochondrial myopathy Completed strategic transaction with Imugene for azer-cel in cancer Extended cash runway through the end of 2025 DURHAM, N.C. /... Read More

DURHAM, N.C. / Nov 01, 2023 / Business Wire / Precision BioSciences, Inc . (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish financial results for the third quarter 2023 and provide a business update on November 7,... Read More

ARCUS showed durable, high-efficiency gene insertion capabilities in NHPs and comparison to CRISPR-Cas9 Data demonstrates ability of ARCUS to achieve large gene excisions enabling significant functional muscle improvement in a DMD mouse model DURHAM, N.C. / Oct 26, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in... Read More

DURHAM, N.C. / Oct 23, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4 th Annual Hepatitis B Virus (HBV) Virtual Conference taking... Read More

DURHAM, N.C. / Oct 12, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster... Read More

DURHAM, N.C. / Sep 27, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application... Read More

Company highlights new preclinical data for wholly-owned and partnered programs following prioritization of in vivo gene editing portfolio Expands portfolio with PBGENE-PMM as a potentially curative treatment for primary mitochondrial myopathy Virtual R&D Day featuring key opinion leaders and members of Precision’s leadership and scientific teams to be held today at 9:00 AM ET DURHAM, N.C. / Sep 12, 2023 / Business Wire /... Read More

DURHAM, N.C. / Sep 06, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in the month of September: H.C. Wainwright Annual Global Investment Conference 2023 Date: September 11, 2023 Time: Available... Read More

DURHAM, N.C. / Aug 31, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET. Precision’s gene editing event will feature presentations from Company management as well as key opinion leaders. The R&D Day event will... Read More

Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patients who Relapse Following CAR T Treatment Upfront Cash and Reduced Operating Expenses Extend Precision’s Expected Cash Runway through Q3... Read More

FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B Company plans to host In Vivo Gene Editing R&D Day on September 12, 2023 Cash Balance Provides Expected Runway Through Q1 2025 DURHAM, N.C. / Aug 04, 2023 / Business... Read More

DURHAM, N.C. / Aug 01, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage... Read More

DURHAM, N.C. / Jul 27, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its lead investigational allogeneic CAR T therapy... Read More

High antiviral activity with substantial and durable reductions in hepatitis B serum antigen and covalently closed circular DNA in preclinical studies of PBGENE-HBV Supports continued PBGENE-HBV development and planned submission of CTA/IND application DURHAM, N.C. / Jun 22, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing... Read More

DURHAM, N.C. / Jun 05, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS ® -based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that members of management will participate in the following investor conferences in June 2023: Jefferies Global Healthcare Conference 2023 Date: Friday, June 9, 2023 Time: 10:30 am ET Goldman Sachs... Read More

Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T Related Adverse Events Were Observed Azer-Cel Achieved 83% Overall Response Rate (ORR), 61% Complete Response (CR) Rate with 55% Durable Response Greater Than or Equal to Six Months Among Evaluable CAR T Relapsed Subjects (n=18)... Read More

DURHAM, N.C. / May 25, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on May 31, 2023 at 8:30 AM ET. Company-Hosted Webcast and Conference Call... Read More

DURHAM, N.C. / May 24, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023. Details for the virtual fireside chat are as follows: Date: Tuesday, May 30, 2023 Time: 2:25 PM ET The... Read More

Late-breaking, oral presentation highlights ability of ARCUS gene editing approach to achieve large gene excisions enabling significant functional muscle improvement in preclinical study DURHAM, N.C. / May 19, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the... Read More

Late-Breaking Abstract Demonstrates Capabilities of ARCUS for Large Gene Excision In Vivo DURHAM, N.C. / May 12, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that its late-breaking abstract presenting preclinical in vivo gene editing data for its PBGENE-DMD program,... Read More

Program Updates Planned for Azer-cel and PBCAR19B in May 2023 Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference In Vivo Gene Editing R&D Day Planned for Mid-2023 Cash Balance Provides Expected Runway through Q1 2025 DURHAM, N.C. / May 09, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company... Read More

DURHAM, N.C. / May 08, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April 27, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment... Read More

DURHAM, N.C. / May 02, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage... Read More

Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis B DURHAM, N.C. / Apr 20, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV... Read More

Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy DURHAM, N.C. / Apr 18, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking abstract featuring preclinical data from... Read More

DURHAM, N.C. / Apr 13, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/606,856, titled “Engineered meganucleases specific for recognition sequences... Read More

DURHAM, N.C. / Mar 27, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023. Details for the company presentation are as follows: Date:... Read More

DURHAM, N.C. / Mar 02, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a... Read More

DURHAM, N.C. / Feb 24, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT). The company announced the promotion of Neil Leatherbury to Senior Vice President, Head of Chemistry,... Read More

DURHAM, N.C. / Feb 22, 2023 / Business Wire / Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023. Details for the virtual fireside chat are as follows: Date: Tuesday, February... Read More

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023. “In 2022, we advanced our corporate priorities strengthening the company and made significant... Read More

FDA feedback signals the Company’s CMC plans shared are in alignment with Agency requirements and expectations CMC regulatory feedback is a critical step in the pathway for development of azer-cel Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA)... Read More

Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T Dose DURHAM, N.C.--( BUSINESS WIRE )-- Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing... Read More